Is there a common genetic basis for all familial cardiomyopathies? by Perrot, A. et al.
 Repository of the Max Delbrück Center for Molecular Medicine (MDC) 
Berlin (Germany) 
http://edoc.mdc-berlin.de/8398/ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Is there a common genetic basis for all familial 
cardiomyopathies? 
 
 
Andreas Perrot, Rainer Dietz, and Karl Josef Osterziel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in final edited form as: 
European Journal of Heart Failure. 2007 Jan; 9(1): 4-6 | doi: 10.1016/j.ejheart.2006.04.010 
Elsevier (The Netherlands) ► 
Final Draft 
MDC Repository | http://edoc.mdc-berlin.de/8398/ 1 
Is there a common genetic basis for all familial cardiomyopathies? 
Andreas Perrot1, Rainer Dietz1, and Karl Josef Osterziel1 
1 Charité-Universitätsmedizin Berlin/Cardiology at Campus Buch & Virchow-Klinikum, and Max Delbrück Center for 
  Molecular Medicine, Berlin, Germany 
 
The most exciting phrase to hear in science, the one that 
heralds new discoveries, is not “Eureka! (I found it!)” but 
rather “Hmm… that's funny…”Isaac Asimov, author and 
biochemist (1920–1992). 
According to the 1995 World Health Organization 
definition, cardiomyopathies are “diseases of the 
myocardium associated with cardiac dysfunction” [1]. 
Traditionally, cardiomyopathies are differentiated 
according to the pathologic changes in cardiac 
morphology and function using cardiac imaging and 
invasive methods to exclude coronary artery disease. The 
two distinct patterns of cardiac remodelling, hypertrophy 
and dilation, are the main criteria for classifying a patient's 
disease as a hypertrophic or a dilated cardiomyopathy; 
cardiac filling is used to define restrictive cardiomyopathy. 
For the practicing physician, hypertrophic (HCM), dilated 
(DCM), and restrictive cardiomyopathy (RCM) are clearly 
distinct disorders. 
The birth of modern cardiomyopathy research is pegged 
to the 1989 publication defining the first genetic locus for 
familial HCM on chromosome 14q1 [2]. In the following 
years, a knowledge explosion took place regarding new 
disease genes and mutations as well as the production of 
gene-targeted animal models (for review see [3] and [4]). 
The field received an additional boost from the completion 
of the human genome project and refined genetic maps, 
as well as the rapid progress in transgenic technologies. 
Whereas HCM is regarded now as a inherited monogenic 
disease [3], familial DCM may occur in about 20% to 50% 
of idiopathic cases (dependent on study population as 
well as criteria and clinical methods used) [5]. Due to this 
fact and the earlier identification of HCM disease genes, 
the number of known mutations is much higher in familial 
HCM compared to familial DCM (as also shown for three 
selected genes in Fig.2). The genetic results of most 
studies underscored the differences in familial 
cardiomyopathies. It was shown that mutations in genes 
encoding for sarcomeric proteins of the thin and thick 
filaments exclusively cause familial HCM while mutations 
in genes encoding for cytoskelatal proteins cause familial 
DCM. As a result, the overall picture seemed well 
structured and conclusive. 
However, the “funny” thing is that reality is more complex 
than our perceptions. Recent studies changed our earlier 
view and showed a substantial overlap in disease-causing 
genes between the three main cardiomyopathy forms 
(see Fig.1). To date, there are eleven genes described 
causing at least two different forms of “pure” heart muscle 
disease. We will select detailed data concerning three of 
these genes as fitting examples for that overlap (see 
Fig.2). 
The most impressive discovery is that mutant cardiac 
troponin I (Fig.2C), a regulatory protein of the thin 
filament, can cause all three cardiomyopathy forms. While 
the first mutations causing HCM were described in 1997 
[6], several years elapsed until mutations in patients with 
RCM and DCM were identified by the McKenna group [7] 
and [8]. The DCM mutation (A2V) appears to be an 
exception, because A2V is transmitted as a recessive trait 
(in contrast to the majority of mutations) and is located at 
the far N-terminal end of the protein. However, no such 
distinction is possible for the HCM and RCM causing 
mutations. Indeed, they cluster very closely in the same 
exons and protein domains at the C-terminus of troponin I. 
A second example involves mutations in the cardiac 
muscle LIM protein (Fig.2B) that can cause both HCM and 
DCM. In families with HCM, we were the first to describe 
mutations in muscle LIM protein (a Z-disk protein) 
suggesting that HCM is not exclusively a disease of the 
thick and thin filaments [9] as confirmed later on by Bos et 
al. [10]. Functional and genetic data from Knoll et al. 
showed that muscle LIM protein also plays an important 
role in DCM [11]. Although all detected mutations cluster 
in the first half of the protein, the DCM mutation K69R is 
located in close proximity to a number of HCM causing 
mutations. 
Last but not least, mutations in titin-cap/telethonin 
(Fig.2A), an additional protein located in the Z-disc, 
resulted in either HCM or DCM. As shown by two groups 
and us [10], [12] and [13], mutations causing 
cardiomyopathies could be distributed over the whole 
gene. Again, no obvious segregation is possible according 
to the form of cardiomyopathy. An HCM mutation could 
follow a DCM mutation located only five codons upstream. 
These discoveries and others not mentioned here suggest 
a common genetic basis for familial cardiomyopathies. 
Although there are a number of DCM genes that do not 
cause either HCM or RCM as far as we know (see Fig.1), 
the cardiomyopathies seem to be true allelic disorders. So 
the next logical step would be to supplement the 
traditional classification of cardiomyopathies by taking into 
account the underlying gene mutations and affected 
molecular structures. Corrado et al. recently suggested 
that cytoskeletalopathies, desmosomalopathies, and 
sarcomyopathies should be distinguished; they also 
integrated the channelopathies, arrhythmogenic disorders 
caused by mutant ion channels [14]. 
Unfortunately, there is still a wide knowledge gap between 
the specific genetic cause and the mechanism producing 
a specific clinical phenotype in all its broad heterogeneity. 
There is no doubt that the kind and localization of a 
mutation, namely the genotype, influences the 
development and expression of the disease. However, 
also certain is the fact that the ultimate phenotype 
represents the sum of all the parts: the influence of RNA 
and protein expression, the complex regulation and 
interaction of these expressed RNA and protein 
molecules, and the predisposition of genetic variation for 
monogenic disease. Further, we do not yet understand 
what happens when an individual mix of genes and 
expression patterns collides with something in the 
environment, such as infectious agents or alcohol. 
A high number of critical signals driving cardiac 
remodelling have been identified in myocyte force  
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generation and transmission and metabolic pathways, as 
well as in calcium homeostasis, apoptosis, and survival 
pathways [15] and [16]. According to Kenneth R. Chien's 
2003 commentary, “the major protagonists and 
antagonists of this (cardiomyopathy) story have yet to 
enter the stage” [17]. To identify all the key players, we 
believe that improved data synthesis from clinical 
sources, namely the patients and their families, with 
experimental data from in vitro and animal experiments is 
urgently need. There is no alternative to an extensive 
dialog between clinicians caring for the patients and basic 
scientists conducting the experiments. Only such 
translational communication can lead us to the “funny” 
insights we need that will provide the new perspectives to 
better understand the familial cardiomyopathies. 
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Fig.1. Overlap of disease genes causing the three main cardiomyopathy forms 
are shown. Twenty genes have been reported of which eleven cause at least 
two different forms of “pure” cardiomyopathy. The cardiomyopathy disease 
genes are: β-myosin heavy chain (MYH7), cardiac troponin T (TNNT2), cardiac 
troponin I (TNNI3), cardiac troponin C (TNNC1), cardiac α-actin (ACTC), α-
tropomyosin (TPM1), myosin-binding protein C (MYBPC3), titin (TTN), titin-
cap/telethonin (TEL), muscle LIM protein (CRP3), metavinculin (VCL), 
cypher/ZASP (LDB3), dystrophin (DMD), δ-sarcoglycan (SGCD), desmin 
(DES), lamin A/C (LMNA), cardiac sodium channel (SCN5A), ATP-sensitive 
potassium channel (SUR2A/ABCC9), phospholamban (PLN), tafazzin (G4.5). 
 
 
 
Fig.2. The distribution of cardiomyopathy-causing mutations in the genes encoding A) titin-cap/telethonin, 
B) cardiac muscle LIM protein, and C) cardiac troponin I. All known mutations in these genes are shown. 
For a better overview, an exception was made for the troponin I mutations causing HCM (in which about 20 
mutations have been described). Mutations causing DCM are shown with yellow arrows, RCM with red 
arrows, and HCM with blue arrows. One-letter symbols are used for the amino acids (AA). The protein 
domains are shown as blocks with the known interaction partners of the respective protein shown below. 
 
